MRM Health Closes $64M Series B Financing Round

MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, has closed a $64 million Series B financing round.

The round was led by French pharmaceutical group Biocodex and included strong participation from German-based ATHOS, as well as new investor BNP Paribas Fortis Private Equity and existing investors SFPIM, Ackermans & van Haaren (AvH), OMX Europe Venture Fund (OMX), Qbic II and VIB.

Proceeds will enable MRM Health to complete a Phase 2b clinical trial for its lead program MH002 in patients suffering from mild-to-moderate ulcerative colitis. MH002 is an advanced Live Biotherapeutic Product (LBP) based on a rationally designed combination of disease-specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD), with positive clinical data in Phase 2a trials showing safety and initial efficacy in both mild-to-moderate ulcerative colitis and in the orphan disease indication pouchitis.

In addition, the company will advance two innovative novel microbial consortia programs to IND approval, targeting inflammation and improved efficacy of immune-oncology therapies, respectively. MRM Health also plans to expand its portfolio of LBPs through strategic partnerships in both human and animal health.

Furthermore, as part of the financing, MRM Health and Biocodex intend to enter a strategic collaboration to develop both novel therapeutic assets and scalable manufacturing capabilities for LBPs. This partnership will provide significant additional non-dilutive funding in the coming years, further strengthening the company’s operational foundation.

“This funding marks a pivotal moment for MRM Health,” said Sam Possemiers, CEO of MRM Health. “With the support of our experienced international investor syndicate, we are now well-positioned to deliver transformative therapies for patients with chronic inflammatory diseases, where current treatments often fall short.”

Also, as part of the Series B financing, Jean-Patrick Hennebelle (Biocodex), Julian Zachmann (ATHOS) and Goedele Ertveldt (SFPIM) will join MRM Health’s Board of Directors.